文献速递前列腺癌

恩扎卢胺在初治与复发非转移性激素敏感性前列腺癌中的作用:前瞻性临床试验的系统综述

Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-04-08

本系统综述通过检索PubMed/Medline数据库,评估恩扎卢胺在非转移性激素敏感性前列腺癌(nmCSPC)初治或挽救治疗中的结局与毒性。初检获401篇文献,最终纳入12项研究(初治7项、挽救治疗5项)。结果表明恩扎卢胺单药替代雄激素剥夺治疗(ADT)或与ADT联合均具潜力,但单药疗效与副作用特征仍需更多试验进一步明确。

要点

  • 恩扎卢胺在nmCSPC初治或挽救治疗中,可单用或与ADT联合。
  • 替代ADT的策略旨在获得等效或更优肿瘤结局并减少治疗相关毒性。
  • 恩扎卢胺单药的疗效与副作用特征仍需更多试验进一步了解。

核心结论

  • 恩扎卢胺作为nmCSPC的治疗策略具有相当大的潜力,可在初治或挽救治疗中单用或与ADT联合。
  • 使用恩扎卢胺替代ADT是一种有吸引力的策略,但需要更多试验来进一步了解恩扎卢胺单药的疗效和副作用特征。

研究设计与样本

  • 系统综述,检索PubMed/Medline数据库,纳入探讨雄激素受体抑制剂在nmCSPC中应用的文章,排除仅讨论转移性或去势抵抗性前列腺癌的文章。
  • 初检检索到401篇文章,其中15篇进行相关性全面评估,最终仔细审查12项具有相关结局的研究。
  • 12项研究中7项专门探讨恩扎卢胺在初治背景中的应用,其余5篇文献专门讨论其在挽救治疗背景中的应用。

主要发现

  • 无论治疗背景如何,数据揭示了两种不同的治疗策略。
  • 第一种策略主张以恩扎卢胺替代ADT,基于实现等效或更优肿瘤结局同时尽量减少治疗相关毒性的前提。
  • 第二种策略采用更传统的方法,即通过加入恩扎卢胺来增强ADT的疗效。

局限性

  • 需要更多试验来进一步了解恩扎卢胺单药的疗效和副作用特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Enzalutamide, a second-generation androgen receptor inhibitor, is indicated for the treatment of metastatic disease, as well as in the treatment of non-metastatic castration resistant prostate cancer (PCa). This systematic review aims to determine outcomes and toxicity in patients with non-metastatic castration sensitive prostate cancer (nmCSPC) treated with enzalutamide in the primary or salvage settings. METHOD: We performed a systematic review focusing on the role of Enzalutamide in the treatment of nmCSPC, using the PubMed/Medline database. Articles focusing on androgen receptor inhibitors in nmCSPC were included, while articles discussing exclusively metastatic or castration-resistant PCa were excluded. RESULTS: The initial search retrieved 401 articles, of which 15 underwent a thorough assessment for relevance. Ultimately, 12 studies with pertinent outcomes were meticulously examined. Among these, seven studies were dedicated to the investigation of enzalutamide in the primary setting, while the remaining five publications specifically addressed its use in salvage settings. Regardless of the treatment setting, our data revealed two distinct therapeutic strategies. The first advocates for the substitution of enzalutamide for androgen deprivation therapy (ADT), based on the premise of achieving equivalent, if not superior, oncological outcomes while minimizing treatment-related toxicity. The second, adopting a more conventional approach, entails augmenting the effectiveness of ADT by incorporating enzalutamide. CONCLUSION: Enzalutamide has considerable potential as a therapeutic strategy for nmCSPC, either used alone or in combination with ADT in the primary or in the salvage settings. The use of enzalutamide instead of ADT is an appealing strategy. However, more trials will be required to further understand the efficacy and side-effect profile of enzalutamide monotherapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shelan M, Achard V, Appiagyei F, et al. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate Cancer Prostatic Dis. 2024. PMID: 38589645. doi:10.1038/s41391-024-00829-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。